ERBB2 and breast cancer: In addition, recent evidence about new drugs show that immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization (ISH) HER2 BC, namely, HER2-low BC, can benefit from HER2-targeted therapy.